Citadel Advisors’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-101,511
| Closed | -$793K | – | 6379 |
|
|
2025
Q1 | $793K | Buy |
101,511
+49,314
| +94% | +$385K | ﹤0.01% | 3530 |
|
|
2024
Q4 | $244K | Buy |
52,197
+6,081
| +13% | +$28.4K | ﹤0.01% | 4713 |
|
|
2024
Q3 | $249K | Buy |
46,116
+15,426
| +50% | +$83.1K | ﹤0.01% | 4437 |
|
|
2024
Q2 | $271K | Buy |
30,690
+30,660
| +102,200% | +$270K | ﹤0.01% | 4395 |
|
|
2024
Q1 | $353 | Sell |
30
-33,821
| -100% | -$398K | ﹤0.01% | 5986 |
|
|
2023
Q4 | $381K | Buy |
33,851
+19,596
| +137% | +$221K | ﹤0.01% | 4010 |
|
|
2023
Q3 | $97.5K | Sell |
14,255
-25,585
| -64% | -$175K | ﹤0.01% | 4854 |
|
|
2023
Q2 | $362K | Buy |
39,840
+1,130
| +3% | +$10.3K | ﹤0.01% | 3941 |
|
|
2023
Q1 | $250K | Sell |
38,710
-3,316
| -8% | -$21.4K | ﹤0.01% | 4450 |
|
|
2022
Q4 | $266K | Buy |
42,026
+15,894
| +61% | +$101K | ﹤0.01% | 4441 |
|
|
2022
Q3 | $162K | Buy |
26,132
+9,469
| +57% | +$58.7K | ﹤0.01% | 4937 |
|
|
2022
Q2 | $147K | Sell |
16,663
-9,803
| -37% | -$86.5K | ﹤0.01% | 5129 |
|
|
2022
Q1 | $223K | Sell |
26,466
-41,427
| -61% | -$349K | ﹤0.01% | 5207 |
|
|
2021
Q4 | $693K | Buy |
67,893
+15,201
| +29% | +$155K | ﹤0.01% | 4247 |
|
|
2021
Q3 | $1.02M | Sell |
52,692
-3,364
| -6% | -$65.3K | ﹤0.01% | 3748 |
|
|
2021
Q2 | $985K | Buy |
+56,056
| New | +$985K | ﹤0.01% | 4031 |
|
|
2019
Q2 | – | Sell |
-10,191
| Closed | -$80K | – | 4873 |
|
|
2019
Q1 | $80K | Buy |
+10,191
| New | +$80K | ﹤0.01% | 4133 |
|